# Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

> **NCT01500278** · PHASE4 · COMPLETED · sponsor: **UCB Pharma SA** · enrollment: 915 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** Certolizumab Pegol (CZP)
- **BIOLOGICAL:** Adalimumab (ADA)
- **DRUG:** Methotrexate (MTX)

## Key facts

- **NCT ID:** NCT01500278
- **Lead sponsor:** UCB Pharma SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-11
- **Final completion:** 2016-01
- **Target enrollment:** 915 (ACTUAL)
- **Last updated:** 2018-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01500278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01500278, "Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01500278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*